Key facts
- Axon Therapies’s last known valuation is $44.5M (Jan 2021).
- It has raised $75.8M across 3 recorded rounds; the latest was Early Stage VC ($7.5M) in Jan 2019.
- Notable investors include Earlybird Venture Capital, Deerfield Management, CDBI Partners, Action Potential Venture Capital, Coridea — 7 tracked in total.
- Axon Therapies has filed 4 Form Ds with the SEC since 2016, most recently Feb 2019 ($7.5M sold to 10 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Axon Therapies
Funding rounds
3 roundsAbout Axon Therapies
Developer of a healthcare device designed to reduce sympathetic nerve activity and address the root cause of heart failure. The company's device allows clinicians to ablate the right greater splanchnic nerve using a small catheter inserted through the groin and helps to normalize sympathetic nervous activity, to shift blood volume from the heart back to the splanchnic bed, reducing pressures in the heart, enabling clinicians to begin treatment quickly, resulting in a high likelihood of successful treatment.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2014
- Employees
- 20
- Website
- axontherapies.com/
- Ownership
- Privately Held (backing)
Axon Therapies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axon Therapies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axon Therapies in its N-PORT filings yet. We sweep new filings monthly.